Patents Assigned to Merck
  • PROCESS FOR THE PREPARATION OF ORGANIC ELECTRONIC DEVICES
    Publication number: 20110227055
    Abstract: The invention relates to the use of a closed field unbalanced magnetron sputter ion plating process in the preparation of organic electronic devices or components thereof, and to organic electronic devices, or components thereof, obtainable by such a process.
    Type: Application
    Filed: November 9, 2009
    Publication date: September 22, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Miguel Carrasco-Orozco, Paul Craig Brookes, Katie Patterson, Frank Egon Meyer, Mark James, Toby Cull, David Christoph Mueller
  • Electrically conductive floor care compositions
    Publication number: 20110227005
    Abstract: The present invention relates to a transparent, electrically conductive floor care composition, in particular for antistatic flooring, which is distinguished by the fact that it comprises one or more conductive pigments.
    Type: Application
    Filed: March 21, 2011
    Publication date: September 22, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Reinhold Rueger, Matthias Kuntz, Christina Maggakis-Kelemen
  • Thiazolyl Mglur5 Antagonists and Methods for Their Use
    Publication number: 20110230526
    Abstract: The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.
    Type: Application
    Filed: January 28, 2011
    Publication date: September 22, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Nicholas D. Cosford, Thomas J. Seiders, Joseph E. Payne, Jeffrey R. Roppe, Dehua Huang, Nicholas D. Smith, Steve F. Poon, Chris King, Brian W. Eastman, Bowei Wang, Jeannie M. Arruda, Jean-Michel Vernier, Xiumin Zhao
  • CATHEPSIN CYSTEINE PROTEASE INHIBITORS
    Publication number: 20110230446
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: May 25, 2011
    Publication date: September 22, 2011
    Applicants: Axys Pharmaceuticals, Inc., Merck Canada Inc.
    Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Chirstophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
  • Fused pyridone M1 receptor positive allosteric modulators
    Patent number: 8022215
    Abstract: The present invention is directed to fused pyridone compounds of formula (I) (I) that are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: September 20, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Douglas C. Beshore, Robert M. DiPardo, Scott D. Kuduk
  • Chiral reactive mesogen mixture
    Patent number: 8021571
    Abstract: The invention relates to chiral reactive mesogen (RM) mixtures, polymer films obtained thereof, and the use of the mixtures and polymer films in optical, electrooptical or electronic components or devices, in decorative, security or cosmetic applications, especially for use in broadband reflective polarizers.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: September 20, 2011
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Alison Linda May, Owain Llyr Parri
  • DIFLUOROPHENYLDIACYLHYDRAZIDE DERIVATIVES
    Publication number: 20110224302
    Abstract: Novel difluorophenyldiacylhydrazide derivatives of the formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in claim 1, are kinase inhibitors and can be used for the treatment of diseases and complaints such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in any type of fibroses, inflammatory processes, tumours and tumour diseases
    Type: Application
    Filed: November 2, 2009
    Publication date: September 15, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Thomas Fuchss, Ulrich Graedler, Norbert Beier, Rolf Gericke, Florian Lang
  • MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS
    Publication number: 20110224134
    Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.
    Type: Application
    Filed: May 20, 2011
    Publication date: September 15, 2011
    Applicants: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SPA, Merck Sharp & Dohme Corp.
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley
  • ANTIFUNGAL AGENTS
    Publication number: 20110224228
    Abstract: Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (1,3)-?-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
    Type: Application
    Filed: August 10, 2009
    Publication date: September 15, 2011
    Applicants: Merck Sharp & Dohme Corp., Scynexis, Inc.
    Inventors: Mark L Greenlee, Robert Wilkening, James Apgar, Donald Sperbeck, Kenneth J. Wildonger, Dongfang Meng, Dann L. Parker, JR., Ahmed Mamai
  • Fused aminopiperidines as dipeptidyi peptidase-IV inhibitors for the treatment or prevention of diabetes
    Patent number: 8017624
    Abstract: The present invention is directed to novel substituted fused aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: September 13, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason M. Cox, Scott D. Edmondson, Anthony Mastracchio
  • Liquid-crystalline medium
    Patent number: 8017200
    Abstract: Disclosed are a liquid-crystalline medium, which contains a compound of formula I and the use thereof for electro-optical purposes, in particular for TN, TFT, IPS or OCB displays.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: September 13, 2011
    Assignee: Merck Patent GmbH
    Inventors: Michael Wittek, Elvira Montenegro, Konstantin Schneider, Brigitte Schuler
  • Pharmaceutically active sulfonyl hydrazide derivatives
    Patent number: 8017628
    Abstract: Sulfonyl hydrazide compounds according to formula I geometrical isomers thereof, optically active enantiomers thereof, diastereomers thereof, racemates thereof, and/or pharmaceutically acceptable salts thereof are useful in method for treating a neuronal disorder, an autoimmune disease, a cardiovascular disease, or cancer in a patient in need of such treatment.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: September 13, 2011
    Assignee: Merck Serono S.A.
    Inventors: Stephen Arkinstall, Serge Halazy, Dennis Church, Montserrat Camps, Thomas Rueckle, Jean-Pierre Gotteland, Marco Biamonte
  • P38 kinase inhibiting agents
    Patent number: 8017605
    Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: September 13, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Soumya P. Sahoo, Meng-Hsin Chen, Kevin D. Dykstra, Hiroo Koyama, Peter T. Meinke, Stephen J. O'Keefe, Ginger Xu-qiang Yang
  • RNA interference mediated inhibition of Stearoyl-CoA desaturase (SCD) gene expression using short interfering nucelic acid (siNA)
    Patent number: 8017761
    Abstract: This invention relates to compounds, compositions, and methods useful for modulating Stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Stearoyl-CoA desaturase (SCD) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of Stearoyl-CoA desaturase (SCD) genes.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: September 13, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James McSwiggen, Leonid Beigelman
  • Classification of breast cancer patients using a combination of clinical criteria and informative genesets
    Patent number: 8019552
    Abstract: The present invention provides prognostic methods for conditions such as cancer, for example, breast cancer, comprising classifying an individual by a plurality of phenotypic, genotypic or clinical characteristics of the condition into a plurality of patient subsets, and analyzing the pattern of expression of prognosis-informative genes identified for that subset in a sample from the individual. The present invention also provides methods for constructing such patient subsets and of identifying prognosis-informative genesets for such subsets. The invention further provides methods of assigning a therapeutic regimen to an individual, microarrays useful for performing prognosis, kits comprising these microarrays, and computer systems and programs for implementing the methods of the invention.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: September 13, 2011
    Assignees: The Netherlands Cancer Institute, Merck Sharp & Dohme Corp.
    Inventors: Hongyue Dai, Laura J. Van't Veer, John Lamb, Roland Stoughton, Stephen H. Friend, Yudong He
  • RNA interference mediated treatment of alzheimer's disease using short interfering nucleic acid (siNA)
    Patent number: 8017765
    Abstract: The present invention concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against beta-secretase (BACE), amyloid precursor protein (APP), pin-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of Alzheimer's disease and any other condition that responds to modulation of BACE, APP, pin-1, PS-1 and/or PS-2 expression or activity.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: September 13, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James McSwiggen, Leonid Beigelman
  • NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
    Publication number: 20110218174
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: October 22, 2009
    Publication date: September 8, 2011
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Jianming Bao, Ping Lan, Huagang Lu, Gergely M. Makara, F. Anthony Romero, Iyassu Sebhat, Dariusz Wodka, Qun Dang, De Michael Chung, Tony S. Gibson, Hongjian Jiang, Daniel K. Cashion
  • Pyrrolopyridinylpyrimidin-2-ylamine derivatives
    Publication number: 20110218198
    Abstract: Compounds of the formula I in which X, R1, R2, R3, R4 and R6 have the meanings indicated in Claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Application
    Filed: June 4, 2009
    Publication date: September 8, 2011
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Margarita Wucherer-Plietker, David Bruce, Dirk Finsinger, Ulrich Graedler, Dieter Dorsch, Christina Esdar
  • Methods for characterizing agonists and partial agonists of target molecules
    Patent number: 8014954
    Abstract: In one aspect, the present invention provides methods of determining whether an agent is more like a partial agonist of a target molecule than a full agonist of the same target molecule. In another aspect, the present invention provides methods to select a candidate compound that may reduce blood plasma glucose concentration in a mammal. Populations of genes are provided that are useful in the practice of the present invention.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: September 6, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yejun Tan, Hongyue Dai, Pek Yee Lum, John Ryan Thompson, Joel Peter Berger, Eric Stanley Muise, Richard F Raubertas, Kenny Kin Chung Wong
  • Liquid-crystalline medium and liquid-crystal display
    Patent number: 8012370
    Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising a dielectrically positive component, component A, comprising a dielectrically positive compound of the formula (I), in which the parameters have the meaning indicated in the specification, and optionally a second dielectrically positive component, component B, comprising one or more dielectrically positive compounds having a dielectric anisotropy of greater than 3 and optionally a dielectrically neutral component, component C, and to liquid-crystal displays, especially to active-matrix displays and in particular to TN, IPS, FFS and OCB displays, containing these media.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: September 6, 2011
    Assignee: Merck Patent GmbH
    Inventors: Michael Wittek, Brigitte Schuler, Volker Reiffenrath, Atsutaka Manabe, Elisabeth Meyer, Mark Goebel